Background: We evaluated the clinical performance of an immunochromatographic (IC) IgM/IgG antibody assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and chest computed tomography (CT) for the diagnosis of Coronavirus disease 2019 (COVID-19).
Methods: We examined 139 serum specimens collected from 112 patients with COVID-19 and 48 serum specimens collected from 48 non-COVID-19 patients. The presence of IgM/IgG antibody for SARS-COV2 was determined using the One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test. Chest CT was performed in COVID-19 patients on admission.
Findings: Of the139 COVID-19 serum specimens, IgM was detected in 27.8 %, 48.0 %, and 95.8 % of the specimens collected within 1 week, 1-2 weeks, and >2 weeks after symptom onset and IgG was detected in 3.3 %, 8.0 %, and 62.5 %, respectively. Among the 48 non-COVID-19 serum specimens, 1 generated a false-positive result for IgM. Thirty-eight of the 112 COVID-19 patients were asymptomatic, of whom 15 were positive for IgM, and 74 were symptomatic, of whom 22 were positive for IgM and 7 were positive for IgG. The diagnostic sensitivity of CT scan alone and in combination with the IC assay was 57.9 % (22/38) and 68.4 % (26/38) for the asymptomatic patients and 74.3 % (55/74) and 82.4 % (61/74) for the symptomatic patients, respectively.
Conclusion: The IC assay had low sensitivity during the early phase of infection, and thus IC assay alone is not recommended for initial diagnostic testing for COVID-19. If RT-qPCR is not available, the combination of chest CT and IC assay may be useful for diagnosing COVID-19.
Keywords: COVID-19; Chest CT scan; Immunochromatographic assay; SARS-CoV-2.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no conflicts of interests.
Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect COVID-19.J Appl Lab Med. 2020 May 19:jfaa079. doi: 10.1093/jalm/jfaa079. Online ahead of print. J Appl Lab Med. 2020. PMID: 32428207
Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics.Clin Chem Lab Med. 2020 Apr 16:/j/cclm.ahead-of-print/cclm-2020-0443/cclm-2020-0443.xml. doi: 10.1515/cclm-2020-0443. Online ahead of print. Clin Chem Lab Med. 2020. PMID: 32301749
Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test.J Med Virol. 2020 Apr 24:10.1002/jmv.25930. doi: 10.1002/jmv.25930. Online ahead of print. J Med Virol. 2020. PMID: 32330303 Free PMC article.
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.J Med Virol. 2020 Feb 27:10.1002/jmv.25728. doi: 10.1002/jmv.25728. Online ahead of print. J Med Virol. 2020. PMID: 32104915 Free PMC article. Review.
SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4016-4026. doi: 10.26355/eurrev_202004_20871. Eur Rev Med Pharmacol Sci. 2020. PMID: 32329877 Review.